Bafna Pharmaceuticals (BAFNAPH) Q4 24/25 earnings summary

Executive summary

• Audited financial results for the quarter and year ended March 31, 2025, were approved, with an unmodified audit opinion from statutory auditors.

• Key appointments: new internal, secretarial, and cost auditors for FY 2025-26 and beyond.

• Achieved Minimum Public Shareholding (MPS) as of April 2, 2025, after promoter share sale.

• Assets of the Madhavaram manufacturing unit classified as held for sale; sale expected in upcoming quarters.

Financial highlights

• Revenue from operations for FY25: INR 15,246.57 lakhs, up from INR 14,585.70 lakhs in FY24.

• Net profit for FY25: INR 415.25 lakhs, down from INR 734.79 lakhs in FY24.

• Q4 FY25 revenue: INR 3,906.00 lakhs; Q4 net profit: INR 131.10 lakhs.

• Exceptional items in FY25: INR 214.56 lakhs, including derecognition of inventory and intangible assets.

• Cash and cash equivalents at year-end: INR 343.27 lakhs, up from INR 139.60 lakhs last year.

Outlook and guidance

• Management expects the sale of the Madhavaram unit to conclude in the coming quarters.

• Steps taken to regularize statutory compliance and seek penalty waiver for past MPS non-compliance.